Monday, August 20, 2018
 
 
Company News: Page (1) of 1 - 02/13/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Potential applications & Growth of Dermatomyositis Drug Market in Pharmaceutical Industry

(February 13, 2018)

NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Dermatomyositis (DM) is an idiopathic (disease for which cause is unknown) inflammatory disorder of skin and skeletal muscle involvement. Patients with skeletal muscle involvement have polymyositis (PM), and patients without muscle damage and typical skin lesions have amyopathic dermatomyositis. Scleromyositis is overlap syndrome associated with anti-PM-Sci antibodies. Dermatomyositis (DM) can be treated with variety of drugs few of them are:

Abatacept – It is also known as Orencia is a protein that prevents body’s immune system from attacking healthy tissues such as joints. It is a prescription medicine used to treat the symptoms of rheumatoid arthritis, also prevent joint damage caused by rheumatoid arthritis.

Baricitinib – It is an oral selective JAK1 and JAK2 inhibitor used in the treatment of rheumatoid arthritis.

Dalazatide – It is formerly known as ShK-186 is a investigational drug designed to selectively target cells that cause autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.

Get complete access of this report: https://www.profsharemarketresearch.com/dermatomyositis-drug-market-report/

Immune globulin intravenous (IGIV)– It is a sterilized solution made from human plasma. Immune globulin contains against the infection from various diseases. GIV is used to treat primary immunodeficiency (PI), and to reduce the risk of infection in chronic lymphocytic leukemia (CLL).

IMO-8400 – It is used in the treatment of Metastatic Melanoma and Dermatomyositis.

Dermatomyositis Drug Market: Application / End User

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

  • Hospital
  • Medical Center
  • Research Institute
  • Clinics

Get free sample of this report: https://www.profsharemarketresearch.com/sample/dermatomyositis-drug-market-report-sample/

Dermatomyositis Drug Market: Product Type

  • Abatacept
  • Baricitinib
  • Dalazatide
  • Immune Globulin
  • IMO-8400

Global Dermatomyositis Drug Market: Competitive Analysis

Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Dermatomyositis Drug Market:

  • MedImmune LLC
  • Neovacs SA
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Hope Pharmaceuticals Inc
  • Idera Pharmaceuticals Inc
  • KPI Therapeutics Inc
  • Marathon Pharmaceuticals LLC

Buy Report: https://www.profsharemarketresearch.com/buy/dermatomyositis-drug-market-report-buy-su/

Dermatomyositis Drug Market report delivers comprehensive analysis of:

  • Market Forecast for 2017-24
  • Market growth drivers

  • Challenges and Opportunities
  • Emerging and Current market trends


  • Market player Capacity, Production, Revenue (Value)
  • Supply (Production), Consumption, Export, Import analysis.
  • End user/application Analysis

Contact Us :

Jeet,

Email- [email protected]

Tel- 1-877-797-7295

www.profsharemarketresearch.com 


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023
  • Disposable Negative Pressure Wound Therapy Devices Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)
  • Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard

    Cancer
  • Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution
  • Singapore's first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  • Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
  • Agenus Receives Second Milestone Payment from Merck
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines